PlayOn11 - Where Fans Become Winners
Revolution’s much-hyped RAS inhibitor hits key survival goals in phase 3 pancreatic cancer trial

Revolution Medicines' pan-RAS inhibitor helped patients with a highly aggressive form of pancreatic...

BUSINESS NEWS April 13, 2026

Revolution’s much-hyped RAS inhibitor hits key survival goals in phase 3 pancreatic cancer trial

Revolution Medicines' pan-RAS inhibitor helped patients with a highly aggressive form of pancreatic cancer live an average of six months longer than...

1 views 0 likes 0 comments
Revolution Medicines' pan-RAS inhibitor helped patients with a highly aggressive form of pancreatic cancer live an average of six months longer than...

Author: Fierce Biotech

Read Original Article

Related News

Top Categories